Cannabis Conundrum

A major global review has linked commercial cannabis legalisation to rising rates of addiction, psychiatric hospital admissions and cannabis use disorder. Researchers at the University of Bath led the study, published in The Lancet Psychiatry. The team tracked cannabis policy changes in dozens of countries from 2000 to 2025. One number stands out immediately: cannabis […]

PMID: 41801216 . DOI: 10.1001/jamainternmed.2025.8215 Abstract Importance: Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects. Observations: Overall, the potential benefits of

Every year, another cohort of teenagers reaches the age where cannabis becomes available to them: through a dealer, a friend, or increasingly, a legal dispensary. Most try it once or twice and move on. A smaller group use it regularly through adolescence. Experts have argued for decades over what that regular use does to a

For many people, cannabis now sits in the same mental basket as a glass of wine or a herbal sleep aid: familiar, legal in some places, and often marketed as a “natural” way to unwind. But a major new brain‑imaging study of more than 1,000 young adults suggests that heavy cannabis use may quietly weaken

Received April 16, 2026; Published online April 22, 2026 DOI: 10.1016/j.lungcan.2026.109421 External Link   Highlights Individuals with cannabis use disorder had an increased risk of any lung and/or bronchus cancer in this cohort study. Increased risk for small cell carcinoma, squamous cell carcinoma, and adenocarcinoma was observed. Further studies are required to explore the strength of this

New Yale study suggests key clinical, cognitive, and brain-based differences. Key points Modern high-potency cannabis may be changing the landscape of psychotic disorders. Cannabis psychosis may be more than a temporary drug-induced condition. Continued cannabis (THC) use may triple relapse risk despite taking antipsychotics. Daily use and high-potency THC increase psychosis risk in a dose-dependent

 Background. Cannabidiol (CBD) now dominates consumer health markets worldwide. Manufacturers market it predominantly on the basis of perceived safety. However, CBD carcinogenicity FDA evidence, generated during the pharmaceutical approval process for purified CBD (Epidiolex, GW Research Ltd, NDA 210365), raises substantive concerns that regulators have not communicated to the public, prescribers, or policymakers. Evidence reviewed. This

Young people who regularly combine cannabis and tobacco face nearly three times the risk of developing a full psychotic disorder. That is the central finding of a landmark study published in Nature Mental Health, and it is one that researchers say demands urgent attention. Dr Heather Ward at Vanderbilt University led the research. Her team

New research from King’s College London asks one of the most pressing questions in mental health science: why does cannabis use raise the risk of psychosis in some people but not others? Scientists published the findings in Biological Psychiatry: Global Open Science in 2026. They point to a complex web of shared genes and biological pathways